Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine - Wikidata - awgldk - TriplyDB

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

http://www.wikidata.org/entity/Q35640645

about

Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP)Vaccines: from empirical development to rational design Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens Clinical development of Ebola vaccines Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Advances and future challenges in recombinant adenoviral vectored H5N1 influenza vaccines Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1 A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?Adenoviral vectors as novel vaccines for influenza.CD4+ T-cell epitope prediction using antigen processing constraints Current views on the potential for development of a HIV vaccine.Control of SIV infection and subsequent induction of pandemic H1N1 immunity in rhesus macaques using an Ad5 [E1-, E2b-] vector platform.HIV-1 Vaccine Trials: Evolving Concepts and Designs Novel directions in HIV-1 vaccines revealed from clinical trials Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial.Epitope-Specific Vaccination Limits Clonal Expansion of Heterologous Naive T Cells during Viral Challenge Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef vaccine induced immune responses.Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.The influence of delivery vectors on HIV vaccine efficacy Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques.Preferential infection of human Ad5-specific CD4 T cells by HIV in Ad5 naturally exposed and recombinant Ad5-HIV vaccinated individuals A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity.A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.MRKAd5 HIV-1 Gag/Pol/Nef vaccine-induced T-cell responses inadequately predict distance of breakthrough HIV-1 sequences to the vaccine or viral load.CD154 and IL-2 signaling of CD4+ T cells play a critical role in multiple phases of CD8+ CTL responses following adenovirus vaccination.Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans A KALA-modified lipid nanoparticle containing CpG-free plasmid DNA as a potential DNA vaccine carrier for antigen presentation and as an immune-stimulative adjuvant.HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial Immunology. Immune activation with HIV vaccines A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.Rare serotype adenoviral vectors for HIV vaccine development.Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials.The number of Toll-like receptor 9-agonist motifs in the adenovirus genome correlates with induction of dendritic cell maturation by adenovirus immune complexes Fitness-Balanced Escape Determines Resolution of Dynamic Founder Virus Escape Processes in HIV-1 Infection.Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals

P2860

Q21034050-1A5AA346-01D9-44F2-996A-7BFDA65BA4E6 Q21089599-EB0A4CF3-2310-489B-8177-AB269D5FB3E3 Q26750912-C9F45D99-BEB8-4CE1-96AB-688D5997E531 Q26775792-F156AB89-C39A-4B04-A9F2-F8EF268C9349 Q26865388-65F76A15-3764-4B3B-8609-7F23C9E099BF Q27013568-9112230F-B6E9-4F7B-AB8E-78FAF232E830 Q27321063-C7C0B8D0-C030-4D0E-8611-8E65055E5CB3 Q29994671-0F0BBEC1-B3A1-41EC-8DAA-891D606028D3 Q30370445-B930FD7D-AE03-4D1C-BF3C-ED4611EEFF16 Q30384608-09A113FA-78B4-4D69-A641-DE4D61B53778 Q30397595-9180F4BA-288D-4680-A09E-60B2688D75FD Q30422006-D412A406-AD6A-4560-85B3-9F1E2479F216 Q30425520-F0832071-CA0A-4B2D-842B-908C094719B9 Q33645528-F32BEB16-CCEE-42FE-B372-4B45E605ABC2 Q33742529-6A6F3913-6483-4185-8C11-59E10BD52EB3 Q33875160-12A00925-2E62-4249-8BF4-EF2ADF2985AA Q33889670-CD92A977-64C8-47A1-A24B-0563989ACA49 Q33999615-820A11B8-832E-4526-ACE4-726C03B02208 Q34057942-80C24245-C09E-4224-B82C-9C6662544116 Q34077543-844B4383-A65A-479D-ADCF-5C3341DF520B Q34155550-CD57E23D-627B-4C3D-B970-1D652220AC32 Q34218500-CF4CCA74-E2F2-472D-8623-3EE45B0AD0E7 Q34359593-2B3673A2-028D-40B2-A16F-E3F6DE4B6B43 Q34369139-E893FF6B-944A-4A9E-BD59-6F1E2D908306 Q34405131-A0569288-B896-408A-9570-2540DFF92B9C Q34447762-239F639E-C04C-43E3-820F-595FDEAC6E3F Q34450043-FE76315E-A294-4850-A864-F1AB090A6A91 Q34806497-445FB9C6-2BCE-4010-9A65-13ACBC959EC4 Q35055188-2FD0D655-6FA4-42F5-9AAA-543C64E077B1 Q35089025-FB6C2423-7E6E-4C15-AAC1-F9A43367EA01 Q35140001-9924AB44-9326-4405-8458-837A75DC4CEE Q35551760-5F2E075C-E69A-4513-A2AD-20A1D30E112E Q35593139-03FEB5AC-FCCE-4401-AB48-9A9E01979371 Q35640650-951BB074-1C91-4F06-9387-1171434714E7 Q35762443-8EF6926F-B6F1-4264-9049-9E52419566CB Q35858437-AC41663B-0B54-4EA5-A5AE-3C71AFB55AB1 Q35919760-F54FBA1E-BBDC-4C0C-93C9-F704EFF13AA6 Q36023055-061967C4-D751-42AD-9597-8C523969CB3D Q36086336-9CDB53E9-85D8-4740-8B21-2F6EB1C5058E Q36288468-D4128F6D-2467-424F-9834-11283EE6B056

P2860

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

http://www.wikidata.org/entity/Q35640645

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Human adenovirus-specific T ce ...... an Ad5-vectored HIV-1 vaccine

@ast

Human adenovirus-specific T ce ...... an Ad5-vectored HIV-1 vaccine

@en

type

label

Human adenovirus-specific T ce ...... an Ad5-vectored HIV-1 vaccine

@ast

Human adenovirus-specific T ce ...... an Ad5-vectored HIV-1 vaccine

@en

prefLabel

Human adenovirus-specific T ce ...... an Ad5-vectored HIV-1 vaccine

@ast

Human adenovirus-specific T ce ...... an Ad5-vectored HIV-1 vaccine

@en

P1433

Q35640645-18FEA6FA-16D9-49AA-800F-A0834574EF2C

P1476

Q35640645-D16C4EDD-A600-4191-B72F-DD4217F0DDB0

P2093

Q35640645-0482EE43-0E08-47A3-B7FE-196F0A1D46EA

Q35640645-0828C4A4-5A28-4D51-BA95-E7527EF53774

Q35640645-106F8C92-7364-48B3-9710-72010E47DF89

Q35640645-7344E5A9-A109-420A-B246-73E4E789B35C

Q35640645-769F2605-4D3C-47AE-9038-14C11552B991

Q35640645-8B4535C0-1C44-47DE-887F-5E91CC6A824B

Q35640645-9AE87BAB-F0A6-4FF0-A688-EE22FC3FCFEC

Q35640645-A2C91A06-C189-4F36-86A6-9FE5EDFA8EC3

Q35640645-B2400880-E40C-4FD1-8289-7FD5FDE9D117

Q35640645-C1CD7277-E20D-4406-BEC3-D0A726E6A6D4

P2860

Q35640645-02433522-FC9D-4FD1-9894-DBE7D9E1316D

Q35640645-2C9FEECD-5E63-4047-BD69-F4EFAA2B2D2F

Q35640645-4527ACF5-258D-4059-8AB6-05EAD843EAFE

Q35640645-5734786A-C448-4666-B9E7-03BFE02B1904

Q35640645-59E47122-E944-4AAC-963B-EEF427BF09D1

Q35640645-5BA69B2B-03A6-4E87-B5B7-13BDE5DB6B38

Q35640645-60F786D2-E219-40E7-8350-D36FD11BCF2C

Q35640645-7677C996-74F8-46A7-88C2-37E05F187A6F

Q35640645-7BA7FDC5-E601-4954-BED5-E0284033F82B

Q35640645-818B143C-324D-42D1-8E10-ABB9E7DF6F2D

P304

Q35640645-7DC18F83-1C96-4C51-AFAB-AA722493BD13

P31

Q35640645-662DDBE7-DF36-4661-8B5E-F82CF6F9C917

P356

Q35640645-2C0DFA4E-2A0A-4E3A-A67A-A79EF3734741

P407

Q35640645-0ECFFD13-49D6-42B9-8876-861FF2D47B8A

P433

Q35640645-DE266C19-3BD1-446C-BFAA-534562AF2E4D

P478

Q35640645-95AA9962-2F9B-4C22-98EF-D49114554A94

P50

Q35640645-605CB647-F12B-4DB9-ABD9-564BFC6A3DD9

Q35640645-808154CC-D6FA-4BF0-8F16-66462836B431

P577

Q35640645-E21037CA-961B-477D-98B7-5D061F0E9FDA

P698

Q35640645-18B44E46-6CDC-4185-9429-5EAE23BBF467

P921

Q35640645-CC9B588E-F567-4AC3-9144-DBD183347D19

P932

Q35640645-C5B30B94-1111-45CC-8496-24C06AA4622F

P356

P1433

Journal of Clinical Investigation

P1476

Human adenovirus-specific T ce ...... an Ad5-vectored HIV-1 vaccine

@en

P2093

Allan C DeCamp

http://www.w3.org/2001/XMLSchema#string

Ann Duerr

http://www.w3.org/2001/XMLSchema#string

Danilo R Casimiro

http://www.w3.org/2001/XMLSchema#string

David P Friedrich

http://www.w3.org/2001/XMLSchema#string

Donald K Carter

http://www.w3.org/2001/XMLSchema#string

Gregory A Spies

http://www.w3.org/2001/XMLSchema#string

James G Kublin

http://www.w3.org/2001/XMLSchema#string

Michael N Robertson

http://www.w3.org/2001/XMLSchema#string

Nicole Frahm

http://www.w3.org/2001/XMLSchema#string

Olivier D Defawe

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

Novel adenovirus vector-based vaccines for HIV-1.

Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

Host immune responses to chronic adenovirus infections in human and nonhuman primates.

Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells

Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials.

Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells.

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

P304

359-367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI60202

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22201684

http://www.w3.org/2001/XMLSchema#string

P921

P932

3248307

http://www.w3.org/2001/XMLSchema#string